Encouraging Initial Clinical Data Presented from Ph 1 Trial of THE001
“Presenting the first clinical data for THE001 in combination with regional hyperthermia is an important milestone for Thermosome,” said Dr. Frank Hermann, CMO of Thermosome. “The data not only confirm the galenic principle of thermosensitive liposomes releasing almost complete doxorubicin upon heat-triggered regional hyperthermia in humans, but also the safe application to date with no formulation-related adverse events. In addition, the first signs of clinical activity in these heavily pre-treated palliative patients are very encouraging and support our efforts to accelerate the clinical development program in soft tissue sarcoma.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo